Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
The administration negotiated discounts with pharmaceutical companies on 10 drugs prescribed to treat blood clots, cancer, heart disease and diabetes. The discounts will range from 38% to 79% when ...
Celgene was originally a unit of Celanese.In 1986, Celanese completed the corporate spin-off of Celgene following the merger of Celanese with American Hoechst. [3] [4]In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that developed pharmaceuticals to regulate disease-related genes. [5]
Revlimid Small molecule Multiple myeloma. Myelodysplastic syndromes. Celgene: 5,801 821 10 Sofosbuvir: Sovaldi Small molecule Hepatitis C: Gilead Sciences: 5,276 (5,007) 11 Fluticasone propionate/salmeterol: Seretide Advair Small molecule Asthma. Chronic obstructive pulmonary disease. GlaxoSmithKline: 5,227 (778) 12 Rosuvastatin: Crestor Small ...
Reactive airway disease; Reactive arthritis; Reactive attachment disorder (RAD) Reactive attachment disorder of early childhood; Reactive attachment disorder of infancy; Reactive hypoglycemia; Reardon–Hall–Slaney syndrome; Reardon–Wilson–Cavanagh syndrome; Rectal neoplasm; Rectophobia; Rectosigmoid neoplasm; Recurrent laryngeal papillomas
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.. The ...
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies.